C
Christoph Schmid
Researcher at Augsburg College
Publications - 453
Citations - 16405
Christoph Schmid is an academic researcher from Augsburg College. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 57, co-authored 419 publications receiving 14139 citations. Previous affiliations of Christoph Schmid include Ludwig Maximilian University of Munich & Medical University of Graz.
Papers
More filters
Journal ArticleDOI
Actions of Insulin-Like Growth Factors
TL;DR: Three different lines of research and three entirely different observations have led to the discovery of the insulin-like growth factors (IGFs), with the hypothesis that serum induces the formation of factors that mediate the message of growth hormone proven to be valid.
Journal ArticleDOI
Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.
Peter Kurtzhals,Lauge Schäffer,Anders Robert Sorensen,Claus Kristensen,Ib Jonassen,Christoph Schmid,Thomas Trüb +6 more
TL;DR: The combination of the B31B32diArg and A21Gly substitutions provided insulin glargine with a 6- to 8-fold increased IGF-I receptor affinity and mitogenic potency compared with human insulin, and the reduced in vitro potency of insulin detemir might explain why this analog is not as effective on a molar basis as human insulin in humans.
Journal ArticleDOI
Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates.
TL;DR: Using the half-lives of the tracer studies and the levels of the different molecular weight forms of IGF in serum, the production rates for IGF-I and -II were calculated to be 10 mg and 13 mg per day.
Journal ArticleDOI
Donor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working Party
Christoph Schmid,Myriam Labopin,Arnon Nagler,Martin Bornhäuser,Jürgen Finke,Athanasios Fassas,Liisa Volin,Gunham Gurman,Johan Maertens,Pierre Bordigoni,Ernst Holler,Gerhard Ehninger,Emmanuelle Polge,Norbert Claude Gorin,Hans-Jochem Kolb,Vanderson Rocha +15 more
TL;DR: The results confirm that the clinical benefit of donor lymphocyte infusion in the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation (HSCT) is limited to a minority of patients.
Journal ArticleDOI
Sequential Regimen of Chemotherapy, Reduced-Intensity Conditioning for Allogeneic Stem-Cell Transplantation, and Prophylactic Donor Lymphocyte Transfusion in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome
TL;DR: Outcome of patients with refractory disease or with complex cytogenetic aberrations was identical to that of better prognostic subgroups, and Sequential use of intensive chemotherapy, RIC transplantation, and pDLT represents a promising approach to the treatment of high-risk AML and MDS.